HLA-DR PE

HLA-DR PE
Regulatory status
CE IVD
Antigen
HLA-DR
Format
PE
Reactivity
Human
Application
FC (QC tested)
Excitation laser
blue (488 nm)
Variant
100 tests
ED7020
In stock
220.00 USD
Variant
0.1 mg
11-261-C100
In stock
220.00 USD
Product details
References
Application
FC (QC tested)
Reactivity
Human
Description
The reagent HLA-DR PE permits identification and enumeration of cell populations expressing human HLA-DR antigen in whole blood using flow cytometry.
Contents
The reagent contains mouse monoclonal antibody against human HLA-DR antigen (clone MEM-12) which was purified by affinity chromatography and labeled with R-Phycoerythrin (PE). The labeled antibody is diluted at optimum concentration in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide. The content of a vial (2 ml) is sufficient for 100 tests.
Preparation
The purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended for In Vitro Diagnostic Use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Product specific references:

Franke A et al. (2007) Delayed recovery of human leukocyte antigen-DR expression after cardiac surgery with early nonlethal postoperative complications: only an epiphenomenon? Interact Cardiovasc Thorac Surg. [Epub ahead of print]
Sundberg EJ et al. (2007) TCR recognition of peptide/MHC class II complexes and superantigens. Semin Immunol. 19: 262-71
Sheldon S and Poulton K (2006) HLA typing and its influence on organ transplantation. Methods Mol Biol. 333: 157-174
Turesson C (2004) Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Des. 10: 129-143
Tiercy JM (2002) Molecular basis of HLA polymorphism: implications in clinical transplantation. Transpl Immunol. 9: 173-180
Zhu X et al. (1997) A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens. Eur J Immunol 27: 1933-41
Horejsi V et al. (1986): Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens. Tissue Antigens. 28: 288-97
Variant
100 tests
ED7020
In stock
220.00 USD
Variant
0.1 mg
11-261-C100
In stock
220.00 USD